|
PYNNACLE phase 2 clinical trial of rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. |
| |
|
Consulting or Advisory Role - Blueprint Medicines; Endeavor BioMedicines; Flagship Pioneering; Mersana; Merus NV; PMV Pharma; Redona Therapeutics; Relay Therapeutics; Repare Therapeutics; Schrodinger |
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Elevation Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Merus (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Surface Oncology (Inst) |
Travel, Accommodations, Expenses - PMV Pharma |
| |
|
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai; Exact Sciences (Inst); Gilead Sciences; GlaxoSmithKline; Lilly; MSD Oncology (Inst); Novartis (Inst); Pfizer; Seagen |
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; seagen |
| |
|
Consulting or Advisory Role - Abbvie (Inst); Alentis Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Biohaven Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Hookipa Biotech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Normunity (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst); SeaGen (Inst); Synthekine (Inst); Takeda (Inst); Zai Lab (Inst) |
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); ArriVent Biopharma (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); City of Hope (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Syndax (Inst); Systimmune (Inst); Taiho Oncology (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); Vividion Therapeutics (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst) |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Arxeon Therapeutics (I); Fortress Biotech; PathomIQ |
Consulting or Advisory Role - AADi; Bayer; BPGBio; Cadila Pharmaceuticals (I); Daiichi Sankyo; Genome Insight; GI Innovations Inc.; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; MOMA Therapeutics; Mundipharma; Oxford BioTherapeutics; Seagan; SpringWorks Therapeutics; XY One Therapeutics |
Research Funding - Adanate Inc. (Inst); ADC Therapeutics (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Day One Therapeutics (Inst); Deciphera (Inst); Elevation Oncology (Inst); Fog Pharmaceuticals (Inst); Genome & Company (Inst); Gilead Sciences (Inst); GV20 Therapeutics (Inst); Immunitas (Inst); Incyte (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Nuvectis Pharma Inc. (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Transcenta (Inst); Vincerx Pharma (Inst) |
Travel, Accommodations, Expenses - Bayer |
| |
|
Consulting or Advisory Role - Actuate Therapeutics; Taiho Oncology |
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); Mirati Therapeutics; Nextrast (Inst); Novocure (Inst); Nucana (Inst); Seagen (Inst); Surface Oncology (Inst) |
Travel, Accommodations, Expenses - Abbvie; Halozyme; Nucana |
| |
|
Leadership - Next Oncology (Inst) |
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda |
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda |
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst) |
| |
|
Research Funding - BeiGene (Inst); Gilead Sciences (Inst); Hanmi Pharma (Inst); Innovent Biologics (Inst); PMV Pharma (Inst); Stingray Pharmaceuticals (Inst); Vivace Therapeutics (Inst) |
| |
|
Employment - HCA/Sarah Cannon |
Leadership - European Organisation for Research and Treatment of Cancer (EORTC) |
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; BMS; Erasca, Inc; Pfizer |
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carrick Therapeutics (Inst); CASI Pharmaceuticals (Inst); Clovis Oncology (Inst); Crescendo Biologics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fore Biotherapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); HUTCHMED (Inst); Ignyta/Genentech/Roche (Inst); Immunocore (Inst); Immunomedics (Inst); Incyte (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Kronos Bio (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Macrogenics (Inst); Menarini (Inst); Merck KGaA (Inst); Mereo Biopharma (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Nerviano Medical Sciences (Inst); Nurix (Inst); Oxford VacMedix (Inst); Pfizer (Inst); Plexxikon (Inst); PMV Pharma (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst) |
Travel, Accommodations, Expenses - Bicycle Therapeutics; Caris Life Sciences; Erasca, Inc; Repare Therapeutics; Sapience Therapeutics; Seagen |
| |
|
Employment - Next Oncology |
Stock and Other Ownership Interests - 1TRIALSP |
Consulting or Advisory Role - Abbvie; Alentis Therapeutics; Amgen; Anaveon; Astex Pharmaceuticals; Boehringer Ingelheim; Daiichi Sankyo/Lilly; Ellipses Pharma; Genmab; Gilead Sciences; Greywolf; Hengrui Therapeutics; Incyte; Janssen; Marengo Therapeutics; Medpace; Medscape; Pfizer; Roche; Sanofi; Seagen; Skypta; Sotio |
Speakers' Bureau - AEFI; Alcura; Aran; AstraZeneca; CDDF; Doctaforum; ESMO; Fundación ECO; Fundación SEOM; Horizon CME; Karger Publishers; Medscape; MeetingPharma; MSD; Novartis; PPD Global; Roche; Seagen; Springer Nature; Tactics; The Ricky Rubio Fundation |
Research Funding - Anaveon; AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst) |
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst) |
| |
|
Consulting or Advisory Role - AstraZeneca; BMSi; Boehringer Ingelheim; Foundation Medicine; Guardant Health; Janssen; Lilly; MSD Oncology; Novartis; Pfizer; Takeda |
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Foundation Medicine; Janssen; Janssen; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Pfizer; Roche; Sanofi |
Research Funding - AstraZeneca |
Travel, Accommodations, Expenses - Janssen; Roche; Takeda |
| |
|
Consulting or Advisory Role - AstraZeneca; BeiGene; IQvia; Lilly; The Limbic |
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); AtriCure (Inst); Axelia Oncology (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Cullinan Oncology (Inst); Dizal Pharma (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genfleet Therapeutics (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); InventisBio (Inst); InxMed (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Maxinovel (Inst); Relay Therapeutics (Inst); Turning Point Therapeutics (Inst); Tyra Biosciences (Inst); Vivace Therapeutics (Inst) |
| |
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro |
Speakers' Bureau - Clovis Oncology; MSD |
| |
|
Stock and Other Ownership Interests - Asian Microbiome Library |
Honoraria - AstraZeneca; Bayer; BioNTech SE; BMS; Daiichi Sankyo; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; MSD; Roche; Zymeworks |
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Daiichi Sankyo; Eisai; GlaxoSmithKline; Merck; MSD; Roche; Zymeworks |
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Roche |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Experimental Drug Development Centre (EDDC)/A*STAR (Inst); Karyopharm Therapeutics (Inst); MSD (Inst); National Medical Research Council/Ministry of Health Singapore; National Medical Research Council/Ministry of Health Singapore (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Daiichi Sanyo; Merck; Novartis; Roche; Zymeworks |
| |
|
|
| |
|
Consulting or Advisory Role - Bolt Biotherapeutics; Fate Therapeutics; Mersana; PMV Pharma; Summit Therapeutics |
Speakers' Bureau - PMV Pharma |
Research Funding - A2A Pharmaceuticals (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Dragonfly Therapeutics (Inst); Fate Therapeutics (Inst); Genentech (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); Mersana (Inst); ModeX Therapeutics (Inst); Pfizer (Inst); PMV Pharma (Inst); Poseida (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Sotio (Inst); Triumvira Immunologics, Inc (Inst); Volastra Therapeutics (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Rain Oncology; Triumvira Immunologics, Inc |
| |
|
Stock and Other Ownership Interests - Biomab; CDR-Life; Lucence Diagnostics; Morphometrix; Xilis |
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Dr. Reddy's Laboratories; Janssen; Merck; Rigel |
Consulting or Advisory Role - AstraZeneca; Coherus Biosciences; Dr. Reddy's Laboratories; Mirati Therapeutics; Pfizer; Regeneron |
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis |
Travel, Accommodations, Expenses - AstraZeneca; BeiGene; Boehringer Ingelheim; Celgene; Coherus Biosciences; Dr. Reddy's Laboratories; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen |